Your browser doesn't support javascript.
Treatment with a DPP-4 inhibitor at time of hospital admission for COVID-19 is not associated with improved clinical outcomes: data from the COVID-PREDICT cohort study in The Netherlands.
Meijer, Rick I; Hoekstra, Trynke; van den Oever, Niels C Gritters; Simsek, Suat; van den Bergh, Joop P; Douma, Renée A; Reidinga, Auke C; Moeniralam, Hazra S; Dormans, Tom; Smits, Mark M.
  • Meijer RI; Department of Internal Medicine, Amsterdam UMC, Location AMC, Amsterdam, The Netherlands.
  • Hoekstra T; Department of Health Sciences and Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • van den Oever NCG; Department of Intensive Care Medicine, Treant Zorggroep Emmen, Emmen, The Netherlands.
  • Simsek S; Department of Internal Medicine, Northwest Clinics, Alkmaar, The Netherlands.
  • van den Bergh JP; Department of Internal Medicine, Amsterdam UMC, Location VUmc, Amsterdam, The Netherlands.
  • Douma RA; Department of Internal Medicine, Viecuri, Venlo, The Netherlands.
  • Reidinga AC; Department of Internal Medicine, Flevohospital, Almere, The Netherlands.
  • Moeniralam HS; Department of Intensive Care Medicine, Martini Hospital, Groningen, The Netherlands.
  • Dormans T; Department of Internal Medicine, St. Antonius Hospital, Nieuwegein, The Netherlands.
J Diabetes Metab Disord ; 20(2): 1155-1160, 2021 Dec.
Article in English | MEDLINE | ID: covidwho-1286208
ABSTRACT

Purpose:

Inhibition of dipeptidyl peptidase (DPP-)4 could reduce coronavirus disease 2019 (COVID-19) severity by reducing inflammation and enhancing tissue repair beyond glucose lowering. We aimed to assess this in a prospective cohort study.

Methods:

We studied in 565 patients with type 2 diabetes in the CovidPredict Clinical Course Cohort whether use of a DPP-4 inhibitor prior to hospital admission due to COVID-19 was associated with improved clinical outcomes. Using crude analyses and propensity score matching (on age, sex and BMI), 28 patients using a DPP-4 inhibitor were identified and compared to non-users.

Results:

No differences were found in the primary outcome mortality (matched-analysis = odds-ratio 0,94 [95% confidence interval 0,69 - 1,28], p-value 0,689) or any of the secondary outcomes (ICU admission, invasive ventilation, thrombotic events or infectious complications). Additional analyses comparing users of DPP-4 inhibitors with subgroups of non-users (subgroup 1 users of metformin and sulphonylurea; subgroup 2 users of any insulin combination), allowing to correct for diabetes severity, did not yield different results.

Conclusions:

We conclude that outpatient use of a DPP-4 inhibitor does not affect the clinical outcomes of patients with type 2 diabetes who are hospitalized because of COVID-19 infection.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Language: English Journal: J Diabetes Metab Disord Year: 2021 Document Type: Article Affiliation country: S40200-021-00833-z

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Language: English Journal: J Diabetes Metab Disord Year: 2021 Document Type: Article Affiliation country: S40200-021-00833-z